New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod

Valion Bio (NASDAQ:VBIO) outlined new Board Chair Thomas H. Jensen’s priorities for advancing Entolimod, its investigational treatment for acute radiation syndrome.

Rhea-AI Summary

Valion Bio (NASDAQ:VBIO) outlined new Board Chair Thomas H. Jensen’s priorities for advancing Entolimod, its investigational treatment for acute radiation syndrome.

Jensen has chaired the board since September 2026 and is working with management to align priorities with execution. He also serves as CEO and a director of Allarity Therapeutics. Entolimod’s development has received approximately $35.6 million in non-dilutive U.S. government funding and holds FDA Fast Track and Orphan Drug designations for acute radiation syndrome. Jensen sees a longer-term opportunity to explore Entolimod in cancer supportive care. Valion’s wholly owned Velocity Bioworks provides manufacturing support.

Argus 15 min delay 7 alerts

-6.06% vs previous close $2.43 last price 34.0x rel. volume Open Argus

Details

Market Reaction – VBIO

$2.39 – $2.64 Day Range

$2.16M Market Cap

On Oct 5, the day this news came out, the latest delayed price for VBIO is 6.06% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $2.43. Relative volume is exceptionally heavy at 34.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

acute radiation syndrome, toll-like receptor 5, fast track, orphan drug designations, +2 more

6 terms

acute radiation syndrome medical

"potential medical countermeasure for acute radiation syndrome (ARS)"

Acute radiation syndrome is the sudden illness that happens after a person absorbs a large dose of ionizing radiation in a short time, damaging blood cells, the gut, skin, and other organs. Think of it like a severe, internal burn that can impair a person’s ability to heal and fight infection. Investors watch it because outbreaks, accidents, or tests can trigger urgent regulatory action, reshape demand for medical treatments and protective equipment, create liability risks, and affect the operations and stock prices of companies in healthcare, energy, insurance, and related supply chains.

toll-like receptor 5 medical

"investigational Toll-like receptor 5 (TLR5) agonist"

Toll-like receptor 5 (TLR5) is a protein on certain immune cells that acts like a security sensor, detecting a specific component of bacterial tails and triggering an inflammation and immune response. Investors care because drugs or vaccines that activate or block TLR5 can change how the body fights infections or cancer, serving as therapeutic targets or vaccine ingredients; progress or setbacks in TLR5-focused research can materially affect the value and prospects of biotech firms.

fast track regulatory

"holds FDA Fast Track and Orphan Drug designations for ARS"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

orphan drug designations regulatory

"FDA Fast Track and Orphan Drug designations for ARS"

A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.

animal rule regulatory

"evaluated in animal models under the U.S. Food and Drug Administration's"

A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.

cdmo technical

"Valion's wholly owned U.S.-based CDMO, Velocity Bioworks"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN ANTONIO, TX / ACCESS Newswire / October 5, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today outlined the perspectives of its new Board Chair, Thomas H. Jensen, on advancing Entolimod. Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS). Jensen brings more than 20 years of biotechnology and oncology experience and is CEO and a Director of Nasdaq-listed Allarity Therapeutics, Inc.

"A biotech company's prospects depend equally on the promise of its drug candidate and its ability to execute," said Jensen. "Having led Allarity through strategic change, I appreciate the significance of Valion's own transformation earlier this year, and I see many of the key elements for success already in place."

Entolimod's development has been supported by approximately $35.6 million in non-dilutive funding from several U.S. government agencies, and the program holds FDA Fast Track and Orphan Drug designations for ARS. It is also backed by a substantial body of human safety data and by supply chain control through Valion's wholly owned U.S.-based CDMO, Velocity Bioworks. To the Company's knowledge, there is no FDA-approved treatment for gastrointestinal ARS.

"The absence of an approved treatment for gastrointestinal ARS makes Entolimod's potential especially significant," Jensen said. "Longer term, I see an important opportunity in exploring whether the same molecule could address needs in cancer supportive care, where I can draw on my background in oncology diagnostics and drug development."

Since becoming Allarity's CEO in December 2023, Jensen has simplified its capital structure, streamlined the organization and reduced costs while concentrating resources on its lead candidate, stenoparib. During that time, Allarity has advanced its Phase 2 ovarian cancer program, received FDA Fast Track designation for stenoparib, strengthened its intellectual property position and secured drug supply for later-stage development.

As Chair, Jensen is working with Interim CEO Dean Zikria, President, COO and CFO Lisa Wolf, and the Board to align Valion's strategic priorities with execution.

"I have rarely seen a company at this stage with such a substantial scientific, clinical and operational foundation," Jensen said. "Our task now is to build on it with a clear sequence of achievable milestones and disciplined allocation of resources to reach them."

About Thomas H. Jensen

Thomas H. Jensen has served as Chair of Valion Bio's Board since September 2026. He co-founded Allarity Therapeutics in 2004 and has been a Director since July 2022. His prior roles at Allarity include Chief Technology Officer, SVP of Information Technology and SVP of Investor Relations. He established Allarity's laboratory operations in Denmark. His work in reproducible RNA extraction and processing for cancer biopsy analysis helped lay the foundation for Allarity's proprietary Drug Response Predictor (DRP®) platform. He holds a B.S. in Biology from the Technical University of Denmark and pursued further studies at the University of Copenhagen.

About Valion Bio, Inc.

Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.

The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome and has been evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA.

Valion is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company's pipeline includes potential programs in neutropenia and immune dysfunction.

Valion's wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.

For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the continued listing of the Company's common stock on the Nasdaq Capital Market; and the Company's ability to maintain compliance with applicable listing standards on the Nasdaq Capital Market. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Valion's actual results to differ from those contained in the forward-looking statements, see Valion's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as required by applicable law.

Investor and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com

SOURCE: Valion Bio, Inc.

View the original press release on ACCESS Newswire